Atlas Trials

Evaluating Comparative Effectiveness of Empagliflozin in Type 2 Diabetes Population With and Without Chronic Kidney Disease

Clinical trial NCT05465317 · COMPLETED

Trial details

NCT number
NCT05465317
Sponsor
Boehringer Ingelheim
Status
COMPLETED
Study type
OBSERVATIONAL
Diabetes Mellitus, Type 2
Start date
2022-08-08
Primary completion
2023-05-02
Enrollment
62197

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.